COMPLETES ACQUISITION OF ADAMS

January 30, 2008                                

                  RECKITT BENCKISER COMPLETES ACQUISITION OF                   

                     ADAMS RESPIRATORY THERAPEUTICS, INC.                      

Reckitt Benckiser Group plc (RB.L) ("Reckitt Benckiser") today announced the
successful completion of its acquisition of Adams Respiratory Therapeutics,
Inc. (NASDAQ: ARxT) ("Adams") through a cash tender offer followed by a
short-form merger of its indirect wholly owned subsidiary, Twickenham Inc.,
with and into Adams. As a result of this acquisition, Adams becomes an indirect
wholly owned subsidiary of Reckitt Benckiser.

At the effective time of the merger, all outstanding shares of Adams common
stock not validly tendered and accepted for payment in the tender offer were
converted into the right to receive US$60.00 per share in cash (the same price
paid in the tender offer), without interest and subject to applicable
withholding of taxes. American Stock Transfer & Trust Company, acting as the
paying agent for the merger, will mail to the remaining former shareholders of
Adams materials necessary to exchange their former Adams shares for such
payment.  As a result of the merger, Adams shares will be delisted and cease to
trade on the NASDAQ Global Select Market.

For Further Information

Reckitt Benckiser                                        [phone]  
                                                                               
Mark Wilson               Corporate Controller and Acting Head of Investor     
                          Relations (investor queries)                         
                                                                               
Fiona Fong                Head of Corporate Communications (press queries)     
                                                                               
PR Agency                                                                      
                                                                               
Susan Gilchrist           Brunswick                      [phone]  
                                                                               
Cindy Leggett Flynn       Brunswick New York             [phone]       
                                                                               
Adams Respiratory                                                              
Therapeutics                                                                   
                                                                               
Janet M. Barth            SVP Investor Relations &       [phone]       
                          Corporate Communications                             
                                                                               
Faith Pomeroy-Ward        Sr. Manager Investor Relations [phone]       
                          & Corporate Communications                           

Notes for Editors

Reckitt Benckiser is a world leader in household cleaning, health and personal
care. The Company is truly global, with over 60 operating companies and some 43
manufacturing facilities worldwide and has sales in 180 countries. Reckitt
Benckiser employs 22,000 people around the world. Amongst the Company's leading
brands in household are Lysol, the world leader in disinfecting cleaning,
Calgonit & Finish & Electrasol, the world leaders in automatic dishwashing,
Woolite, world leader in fine fabrics, Vanish & Spray'nWash, world leaders in
fabric treatment, Airwick and Mortein, both No.2 brands in air care and pest
control respectively. In Health & Personal Care (25% of net revenues), leading
brand positions include Veet, the world number one depilatory and Dettol the
world's leading antiseptic, Nurofen, the leading European analgesic, Strepsils,
world number one in medicated sore throat, Gaviscon the No.1 gastro intestinal
remedy in UK and Lemsip the UK no.1. in cold/flu remedies.

Reckitt Benckiser is headquartered in Slough just outside London, UK and is
listed on the London stock exchange. Reckitt Benckiser had net revenues of £
4.92bn, operating profit of £910m, and net income of £674m in 2006.

About Adams Respiratory Therapeutics, Inc.

Adams is a specialty pharmaceutical company focused on the late-stage
development, commercialization and marketing of over-the-counter and
prescription pharmaceuticals for the treatment of respiratory disorders.